Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug

被引:167
作者
Hanafy, A.
Spahn-Langguth, H.
Vergnault, G.
Grenier, P.
Grozdanis, M. Tubic
Lenhardt, T.
Langguth, P. [1 ]
机构
[1] Univ Mainz, Dept Biopharmaceut & Pharmaceut Technol, D-55099 Mainz, Germany
[2] Kafrelsheikh Univ, Fac Vet Med, Dept Pharmacol, Kafrelsheikh, Egypt
[3] German Univ Cairo GUC, Dept Pharmaceut Chem, Cairo, Egypt
[4] Skyepharma AG, Muttenz, Switzerland
关键词
absorption; bioavailability enhancement; oral drug delivery; nanosuspension; rat; nanomedicine; nanotechnology;
D O I
10.1016/j.addr.2007.04.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
An increasing number of newly developed drugs show bioavailability problems due to poor water solubility. Formulating the drugs as nanosuspensions may help to overcome these problems by increasing saturation solubility and dissolution velocity. In the present study the bioavailability of the poorly soluble fenofibrate following oral administration was investigated in rats. Four formulations were tested: a nanosuspension type DissoCube((R)), one solid lipid nanoparticle (SLN) preparation and two suspensions of micronized fenofibrate as reference formulations, one suspension in sirupus simplex and a second in a solution of hydroxyethy-cellulose in physiological saline. Both colloidal drug delivery systems showed approximately two-fold bioavailability enhancements in terms of rate and extent compared to the reference formulations. No significant differences were found in AUC(0-22) h as well as in C-max and t(max) between the two colloidal delivery systems. In conclusion, nanosuspensions may be a suitable delivery system to improve the bioavailability of drugs with low water solubility. (c) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:419 / 426
页数:8
相关论文
共 19 条
  • [1] BRITTAIN HG, 1995, PHYS CHARACTERIZATIO, V70, P327
  • [2] Inhibition of P-glycoprotein by D-α-tocopheryl polyethylene glycol 1000 succinate (TPGS)
    Dintaman, JM
    Silverman, JA
    [J]. PHARMACEUTICAL RESEARCH, 1999, 16 (10) : 1550 - 1556
  • [3] Dollery C., 1999, THERAPEUTIC DRUGS
  • [4] In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs
    Dressman, JB
    Reppas, C
    [J]. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, 2000, 11 : S73 - S80
  • [5] Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions
    Granero, GE
    Ramachandran, C
    Amidon, GL
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (09) : 917 - 922
  • [6] HEINZEL WR, 1993, TOPFIT PHARMACOKINET
  • [7] Effect of particle size reduction on dissolution and oral absorption of a poorly water-soluble drug, cilostazol, in beagle dogs
    Jinno, J
    Kamada, N
    Miyake, M
    Yamada, K
    Mukai, T
    Odomi, M
    Toguchi, H
    Liversidge, GG
    Higaki, K
    Kimura, T
    [J]. JOURNAL OF CONTROLLED RELEASE, 2006, 111 (1-2) : 56 - 64
  • [8] Nanosuspension formulations for low-soluble drugs: Pharmacokinetic evaluation using spironolactone as model compound
    Langguth, P
    Hanafy, A
    Frenzel, D
    Grenier, P
    Nhamias, A
    Ohlig, T
    Vergnault, G
    Spahn-Langguth, H
    [J]. DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2005, 31 (03) : 319 - 329
  • [9] Liversidge G. G., 1991, US Patent, Patent No. 5145684
  • [10] PARTICLE-SIZE REDUCTION FOR IMPROVEMENT OF ORAL BIOAVAILABILITY OF HYDROPHOBIC DRUGS .1. ABSOLUTE ORAL BIOAVAILABILITY OF NANOCRYSTALLINE DANAZOL IN BEAGLE DOGS
    LIVERSIDGE, GG
    CUNDY, KC
    [J]. INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 125 (01) : 91 - 97